LAVA Therapeutics BV (LVTX): Price and Financial Metrics
LVTX Price/Volume Stats
| Current price | $1.30 | 52-week high | $2.52 |
| Prev. close | $1.29 | 52-week low | $0.85 |
| Day low | $1.28 | Volume | 8,600 |
| Day high | $1.30 | Avg. volume | 266,468 |
| 50-day MA | $1.26 | Dividend yield | N/A |
| 200-day MA | $1.38 | Market Cap | 34.20M |
LVTX Stock Price Chart Interactive Chart >
LAVA Therapeutics BV (LVTX) Company Bio
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates
LVTX Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LVTX Price Returns
| 1-mo | 3.75% |
| 3-mo | -9.72% |
| 6-mo | -26.55% |
| 1-year | -42.98% |
| 3-year | -53.07% |
| 5-year | N/A |
| YTD | 36.70% |
| 2024 | -39.81% |
| 2023 | -54.86% |
| 2022 | -36.36% |
| 2021 | N/A |
| 2020 | N/A |